For additional information, please contact Andrew Dobos at +184.108.40.20651.
Pfizer Ophthalmics Carl Camras Translational Research Award nomination and review
The ARVO Foundation Board of Governors, ARVO Board of Trustees and the ARVO Foundation Awards Committee encourage all members of the vision research community to nominate deserving colleagues for these prestigious awards.
Eligibility, criteria and general guidelines
Eligible nominees must meet the following criteria:
- Early career researchers, who are no more than 45 years old at the time of nomination.
- Exhibit excellence in research and their fundamental scientific discoveries, concepts and novel technologies
- The discovery or observation must have led to, or have the promise of leading to, clinical applications
- Neither nominees nor nominators are required to be ARVO members.
- Foundation and ARVO Officers, Board members and Awards Committee members are not eligible to nominate or be nominated for an award during their terms, or to offer seconding letters of support.
- Nominators and seconders may only support one nomination, and should not be from the same institution as the nominee.
- Previous recipients of the ARVO/Pfizer Translational Research Awards are not eligible.
- All nominations must be submitted electronically.
- Name of Nominee is submitted to confirm eligibility of the nominee, and your eligibility as the nominator. Eligibility will be confirmed within 3 business days. At that time you will be provided the link to submit the nomination.
- Submission of Nomination - must be completed online in one session.
The following must be submitted online.
- Letter of Nomination - One letter of nomination from the nominator, describing in detail the contributions of the nominee and the impact of his/her translational research.
- Indication of nominee's translational research having relatively immediate practicality for clinical care. Such support might consist of the following, but is not limited to these examples:
- The research has lead to an intervention-drug or device, for example- that is currently in Phase 1, 2 or 3 clinical trials
- The research has led to a finding, like smoking and risk of AMD, that is now generally accepted and could result in preventive strategies.
- The research provides strong, original evidence for change in clinical practice, such as overnight contact lens wear and risk of infection.
NOTE: Research that has possible translational implications at a later stage of development, such as snp polymorphisms associated with disease that have not yet lead to interventions, are not appropriate for this award.
- The names of three Seconders, their institutions and e-mail addresses – The nominator is responsible for contacting three individuals who are closely familiar with the nominee's work and who support the award nomination and request that he/she submit a brief letter (no more than one page) electronically to email@example.com by the Sept. 30, 2015 deadline.
- A brief Summary Statement (approximate 75 words).
- The nominee's five most significant articles must be referenced individually in the nomination form.
- The nominee's current curriculum vitae, including full bibliography, and no more than one page listing presented lectures. Abstracts should not be included.
- The Nominator will be notified when all materials, including seconding letters have been received.
The ARVO Foundation Awards Committee will review all nominations and prepare a rank-ordered list of the nominees and submit its recommendations to the Foundation Board of Governors and the ARVO Board of Trustees for the final decision. In some years, the ARVO Foundation Awards Committee may recommend fewer than three nominees for these awards.
All nominations are for one year. Nominations may be resubmitted for a future year if unsuccessful.